Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 166Genitourinary 122Other hematologic neoplasm 50Plasma cell 19Myeloid 8Sarcoma 4Dermatologic 4Tumor-Agnostic 3Thoracic 3Breast 2Other solid neoplasm 1CNS 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1

Interventions

Trastuzumab 260Paclitaxel 215Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 67Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 45Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Prednisone × Breast × Clear all
NCT01517802 2022-05-10

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Janssen Research & Development, LLC

Phase 3 Completed
32 enrolled 7 charts
Breast

Breast Neoplasms

NCT01381874 2019-04-11

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Janssen Research & Development, LLC

Phase 2 Completed
297 enrolled 19 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡